Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress…
By Dr. Matthew Watson
NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announces that it will be presenting a poster during the 29th European Academy of Dermatology and Venereology (EADV) Congress being held virtually October 28 – November 1, 2020. The presentation will be posted onto Akari’s website.
Go here to read the rest:
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress...
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
By Dr. Matthew Watson
GAITHERSBURG, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced updates on its Phase 3 clinical development program of NVX-CoV2373, its COVID-19 vaccine candidate. NVX?CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix?M™ adjuvant. The Company also announced that it will present data from its ongoing Phase 1/2 clinical trial, including new Phase 2 reactogenicity data, on Friday, October 30 during the United States (U.S.) Center for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) meeting.
Read this article:
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event
By Dr. Matthew Watson
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, and Chief Scientific Officer, Dr. Kenneth Cundy, will participate on the panel titled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus” at the ROTH Capital COVID-19 Therapeutics in Development Event, being held virtually on October 28, 2020 at 7:30am PT. A live webcast of the presentation will be available for attendees who register at https://roth.zoom.us/webinar/register/WN_FF_LgnOeQmm7VsRye97DtQ.
Excerpt from:
CohBar to Participate at ROTH Capital COVID-19 Therapeutics in Development Event
Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results
By Dr. Matthew Watson
California cannabis leader to host conference call on November 10, 2020 California cannabis leader to host conference call on November 10, 2020
Link:
Indus Holdings, Inc. to Report Third Quarter 2020 Financial and Operational Results
Galapagos’ R&D Roundtable showcases Toledo program
By Dr. Matthew Watson
Mechelen, Belgium; 27 October 2020, 16.15 CET – Galapagos NV (Euronext & NASDAQ: GLPG) unveils the Toledo target family as a series of salt-inducible kinase inhibitors. Toledo exhibits a dual mode of action characterized by enhanced transcription of anti-inflammatory cytokines and inhibited transcription of pro-inflammatory cytokines. Today, Galapagos also presents new preclinical and healthy volunteer data, and details its broad program to discover and develop multiple series of Toledo compounds with different selectivity profiles, aimed at treating a broad range of autoimmune conditions with important unmet medical need.
Follow this link:
Galapagos’ R&D Roundtable showcases Toledo program
Sanofi: Information concerning the total number of voting rights and shares – September 2020
By Dr. Matthew Watson
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
More here:
Sanofi: Information concerning the total number of voting rights and shares - September 2020
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
By Dr. Matthew Watson
NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders of the Company’s American Depositary Receipts (“ADRs”).
Read more:
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed…
By Dr. Matthew Watson
Initial results from pilot Phase 1/2 clinical trial in patients with locally advanced pancreatic cancer presented during virtual ASTRO Annual Meeting
Read the rest here:
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed...
Lumos Pharma to Report Third Quarter 2020 Financial Results and Host a Conference Call on November 10, 2020
By Dr. Matthew Watson
AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2020 financial results after market close on Tuesday, November 10, 2020. The company will host a conference call and webcast at 4:30 PM ET that day to discuss its third quarter financial results and provide an update on corporate activities. There will also be a question and answer session following the prepared remarks.
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2020 Financial Results on November 10, 2020
By Dr. Matthew Watson
SAN FRANCISCO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020.
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
By Dr. Matthew Watson
SAN DIEGO and TORONTO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020, after the close of the market.
Read the original post:
Aptose to Release Third Quarter Ended September 30, 2020 Financial Results and Hold Conference Call on November 10, 2020
Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
By Dr. Matthew Watson
SANTA MONICA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial results after the financial markets close on Thursday November 12, 2020.
Read the original:
Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic…
By Dr. Matthew Watson
WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock. ARTeSYN Biosolutions is projected to generate approximately $30 million in revenue (pro forma) in 2020, led by the success of its single-use chromatography and filtration systems which are considered the gold standards in downstream bioprocessing due to their performance, automation and low hold-up volumes. The proposed acquisition of ARTeSYN, combined with the recent acquisitions of Engineered Molding Technologies (“EMT”) and Non-Metallic Solutions (“NMS”) further establishes Repligen as a premier player in single-use systems and associated integrated flow path assemblies.
Continue reading here:
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic...
Transactions in connection with and conclusion of share buyback program
By Dr. Matthew Watson
Company announcement no. 42 - 20 27 October 2020
Read more:
Transactions in connection with and conclusion of share buyback program
CLINUVEL to Trial Innovative Drug in Stroke
By Dr. Matthew Watson
Read the original:
CLINUVEL to Trial Innovative Drug in Stroke
Supernus to Host Third Quarter 2020 Financial Results Conference Call
By Dr. Matthew Watson
ROCKVILLE, Md., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report business results for the third quarter of 2020 after 5:00 p.m. ET on Tuesday, November 3, 2020.
Link:
Supernus to Host Third Quarter 2020 Financial Results Conference Call
ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants
By Dr. Matthew Watson
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
Read more here:
ProMIS Neurosciences Announces Up to $3 Million Private Placement Offering of Special Warrants
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride…
By Dr. Matthew Watson
New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020 New analysis of contemporary real-world data presented at American Society of Nephrology (ASN) Kidney Week 2020
The rest is here:
U.S. Veterans with Decreased Renal Function Shown to Be at Higher Risk for Adverse Cardiovascular Events if They Have Moderately Elevated Triglyceride...
Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2020 Financial and Operational Results on November 6, 2020
By Dr. Matthew Watson
BEDMINSTER, N.J., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Friday, November 6, 2020 at 8:30 a.m. ET to discuss operational and financial results for the third quarter ended September 30, 2020.